National Bank of Canada’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

National Bank of Canada’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5	Closed	-$19	–	2955
2023 Q3	$19	Buy	+5	New	+$34	﹤0.01%	2747
2023 Q2	–	Sell	-5	Closed	-$18	–	2864
2023 Q1	$18	Hold	5	–	–	﹤0.01%	2680
2022 Q4	$160	Hold	5	–	–	﹤0.01%	2708
2022 Q3	$0	Hold	5	–	–	﹤0.01%	2956
2022 Q2	$0	Hold	5	–	–	﹤0.01%	3058
2022 Q1	$0	Hold	5	–	–	﹤0.01%	3081
2021 Q4	$1K	Buy	+5	New	+$844	﹤0.01%	2788

Other funds holding EVLO

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

National Bank of Canada's EVLO Position: Q4 2023 in Review

National Bank of Canada sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 5 shares — an estimated $19 sold.

National Bank of Canada first reported a position in EVLO in Q4 2021 and held it in 7 quarters. The position peaked at $1K in Q4 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.

National Bank of Canada reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
National Bank of Canada sold 5 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $19.
National Bank of Canada first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
National Bank of Canada's Evelo Biosciences, Inc. Common Stock position peaked at $1K in Q4 2021.
2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.

Based on National Bank of Canada's 13F filing for Q4 2023, filed 6 Feb 2024.